Lysogene News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

16.02.23	Lysogene Announces the Extension of Deadline for the Submission of Offers (Businesswire)
25.01.23	Lysogene: Conversion of the Safeguard Proceedings Into Reorganization Proceedings (Businesswire)
06.01.23	Lysogene: Launch of a Process to Find Buyers or Investors and Request for Conversion of Safeguard Proceedings Into Reorganization Proceedings (Businesswire)
29.11.22	Lysogene Provides Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study (Businesswire)
18.11.22	Lysogene to Provide Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study and Host Webcast on Wednesday, November 23, 2022 (Businesswire)
07.07.22	Lysogene Provides Additional Update on AAVance Phase 2/3 Gene Therapy Clinical Trial with LYS-SAF302 in children with MPS IIIA (Businesswire)
18.05.22	Lysogene Provides Clinical Update on AAVance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of MPS IIIA at the 25th Annual ASGCT Meeting (Businesswire)
24.02.22	Lysogene Provides Update on Efficacy, Safety and Timelines of the AAVance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of MPSIIIA (Businesswire)
11.02.22	Lysogene Reports Additional Positive Biomarker Data With LYS-SAF302 and Favorable Safety Data With LYS-GM101 Presented at the WORLDSymposium™ 2022 (Businesswire)
07.02.22	Lysogene Provides Medical Update (Businesswire)
13.01.22	Lysogene Announces Termination of License Agreement With Sarepta for LYS-SAF302 Program, Regaining Global Commercial Rights (Businesswire)
08.07.21	Lysogene Announces FDA Fast Track Designation for LYS-GM101 Gene Therapy for the Treatment of GM1 Gangliosidosis (Businesswire)
11.06.21	Lysogene Enters into an Exclusive Worldwide License Agreement with SATT Conectus for a Gene Therapy Candidate for the Treatment of the Fragile X Syndrome (Businesswire)
09.06.21	Lysogene Announces First Patient Dosed with LYS-GM101 Investigational Gene Therapy for the Treatment of GM1 Gangliosidosis (Businesswire)
15.02.21	Lysogene Reports LYS-SAF302 Biomarker Data Presented at the WORLDSymposium™ 2021 (Businesswire)
12.02.21	Lysogene Receives FDA Clearance of Investigational New Drug Application to Initiate the Gene Therapy Clinical Trial in the US with LYS-GM101 for the Treatment of GM1 Gangliosidosis (Businesswire)
11.01.21	Lysogene Receives MHRA and Research Ethics Committee Approvals to Initiate the Gene Therapy Clinical Trial in the UK with LYS-GM101 for the Treatment of GM1 Gangliosidosis (Businesswire)
28.12.20	Lysogene Reports Positive Biomarker Data With LYS-SAF302 (Businesswire)
18.12.20	Lysogene Announces a Change in the Organization of KGA, Minority Shareholder of Lysogene (Businesswire)
19.11.20	Lysogene Reports its Cash Position as of 30 September 2020 (Businesswire)
15.10.20	Lysogene Provides Update on the AAVance Clinical Trial Evaluating LYS-SAF302 in Patients with MPS IIIA (Businesswire)
25.09.20	Lysogene Reports First Half 2020 Financial Results and Provides Operational Update (Businesswire)
01.07.20	Lysogene Announces a Research Collaboration With the Weizmann Institute of Science (Businesswire)
05.06.20	Lysogene announces important updates on AAVance phase 2/3 clinical trial with LYS-SAF302 in MPS IIIA (Businesswire)
14.05.20	Lysogene Announces Presentations at Upcoming Meetings (Businesswire)
29.04.20	Lysogene Reports Its Cash Position as of 31 March 2020 (Businesswire)
22.04.20	Lysogene Reports Full Year 2019 Financial Results and Provides Operational Update (Businesswire)
16.03.20	Lysogene Announces the Date of Its 2020 General Shareholders’ Meeting and Amends Its Financial Calendar (Businesswire)
25.02.20	Lysogene Receives FDA Fast Track Designation for LYS-SAF302 Gene Therapy in MPS IIIA (Businesswire)
17.02.20	Lysogene Reports its Cash Position as of 31 December 2019 (Businesswire)
11.02.20	Lysogene Announces Presentations at Upcoming 16th WORLDSymposium™ on Lysosomal Diseases (Businesswire)
24.01.20	Lysogene Announces Its Corporate Agenda For 2020 (Businesswire)
18.12.19	Lysogene Announces the Publication of an Article in the Scientific Journal "Molecular Therapy Methods & Clinical Development” Demonstrating the Potential of Its Drug Candidate LYS-SAF302 (Businesswire)
20.11.19	Lysogene Reports its Cash Position as of 30 September 2019 (Businesswire)
17.10.19	Lysogene Appoints Mr. Stéphane Durant des Aulnois as Chief Financial Officer (Businesswire)
30.09.19	Lysogene Reports First Half 2019 Financial Results and Provides Operational Update (Businesswire)
26.09.19	Lysogene Announces the Appointment of Carole Deffez as New Independent Board Director (Businesswire)
05.09.19	Lysogene: A Pivotal Year 2019 for Lysogene’s MPS IIIA Phase 2-3 Clinical Trial (Businesswire)
18.07.19	Lysogene Establishes Scientific Advisory Board with International Experts in CNS Gene Therapy (Businesswire)
05.09.18	Lysogene Announces FDA approval of IND Application to Initiate Phase 2-3 Clinical Trial in MPS IIIA (Businesswire)
15.05.18	Lysogene Announces the Nomination of Dr Ralph Laufer as Chief Scientific Officer and Member of the Executive Team (Businesswire)
06.02.18	Lysogene Gets PIP Green Light from European Medicines Agency on MPS IIIA Pivotal Study; Paving Way for Clinical Trial Application Approvals (Businesswire)
01.02.18	Lysogene to Present Five Year Clinical Data in MPS IIIA at the 14th Annual WORLDSymposiumTM (Businesswire)
15.01.18	Lysogene Reports Fourth Quarter 2017 Financial Information (Businesswire)
21.12.17	Lysogene Holds First Clinical Advisory Board Meeting in Mucopolysaccharidosis Type IIIA (MPS IIIA) and GM1 Gangliosidosis (Businesswire)
18.10.17	Lysogene Announces Company Presentations at Upcoming Scientific Conferences (Businesswire)
16.10.17	Lysogene: Financial Information for the Third Quarter of 2017 (Businesswire)
05.10.17	Lysogene to Host Key Opinion Leader Meeting on Gene Therapy for Patients with Sanfilippo Syndrome Type A in New York City (Businesswire)
04.10.17	Lysogene Announces Company Presentations at October & November Investor Conferences (Businesswire)
21.09.17	Lysogene Holds First Parent Advisory Board in MPS IIIA (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.30	1.53 %	K V
Holcim	87.38	1.49 %	K V
Roche Hldg G	251.00	1.46 %	K V
Swiss Re	130.35	1.44 %	K V
UBS Group	27.07	1.35 %	K V
Swisscom	501.00	0.52 %	K V
Lonza Grp	532.40	0.26 %	K V
Nestle	74.08	0.14 %	K V
Sonova Hldg	295.60	0.00 %	K V
Geberit	512.20	-0.39 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Lysogene SA

Aktien Top/Flop

Meistgelesene Nachrichten